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Background: CADASIL is an autosomal dominant genetic leukoencephalopathy linked to mutations in the Notch3
gene. In rare cases, widespread brain lesions on T2 MRI mimicking multiple sclerosis are observed. From a national
registry of 268 patients with adult-onset leukodystrophy, we identified two patients with an atypical presentation of
CADASIL without co-occurrence of another systemic disease.
Case presentations: Patient 1 experienced progressive gait disability and patient 2 relapsing optic neuritis and
sensory-motor deficit in the leg. Both patients responded to corticotherapy and patient 2 was also responsive to
glatiramer acetate. No oligoclonal bands were found in the CSF, and MRI showed myelitis and lesions with
gadolinium enhancement in brain (patient 1) or incomplete CADASIL phenotype (patient 2).
Conclusions: In rare cases, an inflammatory-like process can occur in CADASIL. In these patients,
immunomodulatory treatments, including corticosteroids, could be effective.
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CADASIL is an autosomal dominant vasculopathy that
includes subcortical infarct and leukoencephalopathy.
This disorder is linked to mutations in the Notch3 gene,
mostly located in exons 2-24 [1]. In rare cases, widespread
brain lesions on T2 MRI mimicking multiple sclerosis
(MS) are observed. To go further in the description of this
specific presentation, patients were recruited through a
national registry of 268 patients with adult-onset leukody-
strophy fulfilling the following inclusion criteria: 1. age at
onset above 16 years old; 2. symmetrical white matter in-
volvement on the first MRI examination; 3. absence of
autoimmune and infectious disorder tested by antinuclear,
anti-neutrophil cytoplasmic, anti-phospholipid antibodies,
VIH, lyme and syphilis blood tests, salivary gland biopsy,
fundoscopy, CSF analysis and chest X-ray. Among
them, we identified 23 patients with CADASIL, two of
whom also presented atypical clinical and radiological
signs mimicking MS. We describe these two cases and dis-
cuss the particularities of this inflammatory-like presenta-
tion of CADASIL.* Correspondence: nicolas.collongues@chru-strasbourg.fr
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Patient 1. A 53-year-old woman with no previous
personal or family medical history was
admitted with a 6-month history of
progressive gait disability and urinary
urgency. Neurological assessment revealed
dysesthesia in the feet and mild weakness in
the left leg, brisk tendon reflexes in all four
limbs and a bilateral Babinski sign.
Neuropsychological examination showed a
dysexecutive syndrome.tral Ltd. This is an
/creativecommons
, provided the origBlood samples and CSF analysis were normal,
without any oligoclonal bands. Visual evoked
potentials were normal. Spinal cord MRI
showed thoracic hypersignal on T2-weighted
images without gadolinium enhancement.
Brain MRI showed extensive, bilateral,
symmetrical periventricular and temporal
hypersignal on T2-weighted images. One
lesion, in the right internal capsule, was
detectable on gadolinium-enhanced T1-
weighted images (Figure 1).
A diagnosis of MS was suggested and
treatment with intravenous corticosteroidsOpen Access article distributed under the terms of the
.org/licenses/by/2.0), which permits unrestricted use,
inal work is properly cited.
Figure 1 Brain and spinal cord MRI of patient 1. Flair sequence
showing brain abnormalities typical of CADASIL, involving the
external capsule, typical lacunar infarcts (A), and temporal lobes (B).
Lesion in the right internal capsule (C) were enhanced by
gadolinium injection on the T1-weighted image (D, arrow). A
thoracic spinal cord lesion is noted on the longitudinal T2-weighted
image (E), corresponding to partial myelitis in the transverse plane
(F).
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improvement over the following few weeks.
Owing to the extensive symmetrical lesions
especially involving temporal lobes on brain
MRI and despite the lack of family history of
migraine, stroke or early-onset dementia,
CADASIL was looked for. A missense
mutation was found in exon 3 of Notch3 at
nucleotide 346 (c346C>T), resulting in a
substitution of arginine for cysteine at codon
90. This mutation was not found in 200
Caucasian control individuals, thus
confirming its pathogenic status.Patient 2. A 46-year-old woman with a family history of
MS (one affected cousin) experienced a first
episode of optic neuritis followed by a
sensory-motor deficit in the leg two years
later.
Blood samples and CSF analysis were normal,
without any oligoclonal bands. Visual evoked
potential latencies were increased (128 ms on
both sides). The initial brain MRI showed
large T2-weighted lesions without gadolinium
enhancement; the spinal cord MRI was
normal.
During follow-up, she had experienced acute
worsening once a year for 6 years before the
first disease-modifying therapy and was
responsive to methylprednisolone infusion.
She was then diagnosed with MS and treated
with glatiramer acetate. She experienced
acute worsening of her condition on two
occasions only, during the following 5 years
of therapy. During the follow-up her brother
and sister developed stroke-like episodes and
were diagnosed with CADASIL. Owing to the
aspect of brain MRI (Figure 2), the patient
was also tested for CADASIL, and a missense
mutation in exon 11 of Notch3 was found. A
C-to-T mutation at nucleotide 1750
(c.1750C>T) results in the substitution of
arginine for cysteine at codon 558. This
mutation was not found in 200 Caucasian
control individuals, thus confirming its
pathogenic status. After termination of the
Figure 2 Brain and spinal cord MRI of patient 2. Flair sequence showing brain abnormalities typical of CADASIL (A) including the external
capsule (B) but with numerous atypical findings for CADASIL: absence of temporal lobe involvement (C), cerebellar lesion in the left hemisphere
(D, arrow), large bilateral cavities in the pallidum (E, dotted circles) without any microbleeds on T2*-weighted sequences (F), and a lesion in the
corpus callosum, which has been rarely described in CADASIL (G, arrows).
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recurred once yearly. Glatiramer acetate was
reintroduced and only one relapse occurred
in the following 3 years. A
neuropsychological assessment performed at
the end of the follow-up showed
hippocampal memory impairment,
dysexecutive syndrome and mild depression.Conclusions
We have described two patients from different families
with an inflammatory-like presentation of CADASIL. In
patient 1, a cysteine had replaced arginine at codon 90
and in patient 2 arginine was substituted by cysteine at
codon 558. These two mutations in Notch3 gene, based
on cysteine changes, correspond to the stereotyped muta-
tions found in other reported patients with this diagnosis
and are very likely pathogenic and a cause of CADASIL.
The hallmark of these reports was the atypical clinical and
MRI features in those patients that could rule out a diag-
nosis of CADASIL. The main unusual clinical findings
were myelitis in patient 1 and optic neuritis in patient 2.
Additional atypical findings were the lack of any history of
migraine, corticosensitivity, and the absence of majordisability over a long follow-up. Furthermore, unusual
MRI findings for CADASIL were observed in patient 1:
spinal cord lesion and gadolinium enhancement in the
internal capsule. In patient 2, brain MRI did not show a
typical CADASIL presentation, such as temporal involve-
ment, lacunar infarct or microbleeds.
At first, whereas the diagnosis of CADASIL was genet-
ically proven, in those patients, the occurrence of atyp-
ical presentation including myelitis and optic neuritis
raised the question of an inflammatory process. Despite
the lack of argument for an additional systemic auto-
immune disorder, some findings such as a progressive
spinal cord syndrome or relapsing optic neuritis, a pos-
sible therapeutic response to immunomodulators/corti-
costeroids, and MRI data, seemed to be in favor of MS.
However, in those patients, the absence of oligoclonal
bands and the aspect of extensive leukoencephalopathy
on brain MRI with a microangiopathy aspect argued
against that hypothesis. Furthermore, one should bear in
mind that the improvement after anti-inflammatory
treatment may have been overestimated because some
degree of recovery from small ischemic lesions cannot
be excluded and because the course of other inflamma-
tory diseases of the CNS are often unpredictable.
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ing CADASIL and MS: possibly a progressive form in
patient 1 and a relapsing form in patient 2, fulfilling
the MS diagnostic criteria with the limit that another
diagnosis can be discussed (the no better explanation
criteria). It is to note that, in the literature, no co-
occurrence of CADASIL and MS has been found in any
of 93 MS patients with a family history of MS [2]. Des-
pite those results, we had learned that, from a physio-
pathogenic point of view, genetic or epigenetic events
could play a role to modify the course of diseases,
including notch protein and signalling pathway in
CADASIL and MS [3], or mitochondrial cytopathies
such as Leber’s disease or POLG mutations which have
been suggested to promote MS [4,5].
Another hypothesis is that our patients had atypical
CADASIL in which an inflammatory process occurred
mimicking MS. In the literature, some of the above four
findings evoking MS have, rarely, been associated with
CADASIL, including a steroid-responsive spinal cord
syndrome in one patient [6] and progressive disability in
another patient [7]. The physiopathological mechanism
invoked to explain those particularities in CADASIL
remains unclear and involved chronic hypoperfusion
for progressive disability [8] or T-cell modulation, as
observed in animal models [9]. Increased vascular per-
meability of the blood–brain barrier could also be
hypothesized because the accumulation of Notch-3 re-
ceptor ectodomain in the vascular wall is known to im-
pair its structural and functional stability [10]. At last,
some metabolism disorders may produce new epitopes
like myelin or neuronal debris leading to non specific in-
flammatory reactions as observed in our patients.
The aim of this study was to sensitize clinicians to
such atypical presentations of CADASIL and not to es-
tablish epidemiological data. Selection biases were inher-
ent in the constitution of the CADASIL cohort, because
some patients may not have been declared, while others
may have been classified as MS-patients because muta-
tions in the Notch3 gene have not been researched.
Whatsoever, the reported prevalence of CADASIL
lies between 4 to 15 cases per 100000 [1], which there-
fore makes the co-existence of another rare event
improbable.
In conclusion, inflammatory-like presentation can
occur in CADASIL. This condition should be known to
clinicians because it could represent a challenge to make
the right diagnosis. In these patients, immunomodula-
tory treatments, including corticosteroids, could be ef-
fective and should be proposed in the absence of
validated therapeutic for CADASIL.Competing interests
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